Back to search
Drug-resistant Partial Epilepsy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Drug-resistant Partial Epilepsy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Drug-resistant Partial Epilepsy trials you may qualify forDravet Syndrome (DS) is a severe neurodevelopmental disease, which is predominantly caused by mutations of SCN1A, the gene coding for Nav1.1 voltage-gated sodiu…
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Brain somatic mutations are increasingly recognized as a major cause of focal epilepsies. These include mTOR pathway mutations underlying cortical malformations…
This will be a prospective, pilot, open-label, two-arm, parallel-group, randomized study to evaluate the efficacy and safety of low-intensity focused ultrasound…
Epilepsy is a clinical condition that affects about fifty million people worldwide, with an estimated occurrence of 16-51 new cases per 100,000 people each year…
Epilepsy is a common disease affecting 0.5 to 1% of the general population. Epilepsies refractory to drug treatment lead to increased morbidity, mortality and h…
Transcranial current stimulation (tCS), a safe, tolerable technique employing weak currents (\~ 1 mA) applied to the scalp, has been shown to be a promising tec…
The main objective of this study is to evaluate the feasibility of recording fast-ripples, a potential new biomarker of epilepsy, using the new micro-macroelect…